Controversy over Azar memo highlights concerns about politicization of FDA 

A controversy over a change in administrative procedures at HHS, the kind of action that would usually pass unnoticed, is the result of the super-charged atmosphere at the department and at FDA. 

Concerns that the politicization of regulatory decisions about COVID-19 -- including the appearance that emergency use authorizations were granted to hydroxychloroquine and convalescent plasma to please President Donald Trump -- are eroding public confidence in FDA Commissioner Stephen Hahn and HHS Secretary Alex Azar, according to former HHS officials who spoke with BioCentury...